A Study by ChromaDex to Assess the Effects of TRU NIAGEN on Cognitive Function, Mood and Sleep in Older Adults

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2018
The sponsor of this study is ChromaDex, Inc. This is a double‐blind, randomized, crossover study to investigate the effects of 300 mg/d and 1000 mg/d TRU NIAGEN (nicotinamide riboside) compared to a placebo control on cognitive function, mood and sleep in men and women over 55 years of age. The trial is managed by Midwest Center for Metabolic and Cardiovascular Research.
Epistemonikos ID: 4790b1a094fa885adfb905baef05eaae9f4c9007
First added on: May 21, 2024